Androgen receptor drives cellular senescence

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Mirochnik, Yelena ^a   Veliceasa, Dorina ^a   Williams, Latanya ^a   Maxwell, Kelly ^a   Yemelyanov, Alexander ^b   Budunova, Irina ^b   Volpert, Olga V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; CYTOKINE; EOTAXIN; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PROTEIN BCL 2; PROTEIN GRO ALPHA; PROTEIN P21; PROTEIN P53; PROTEIN P63; RANTES; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST; CKAP4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FLUTAMIDE; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL DESTRUCTION; CANCER INHIBITION; CARCINOGENICITY; CELL AGING; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

ANDROGEN RECEPTOR ANTAGONISTS; CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; FLUTAMIDE; HUMANS; MEMBRANE PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84857697411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031052     Document Type: Article

References (66)

1. Culig Z, Bartsch G, (2006) Androgen axis in prostate cancer. J Cell Biochem 99: 373-381.
2. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225.
3. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, et al. (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92: 221-236.
4. Litvinov IV, De Marzo AM, Isaacs JT, (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88: 2972-2982.
5. Eder IE, Haag P, Bartsch G, Klocker H, (2005) Targeting the androgen receptor in hormone-refractory prostate cancer-new concepts. Future Oncol 1: 93-101.
6. Vander Griend DJ, Litvinov IV, Isaacs JT, (2007) Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 6: 647-651.
7. Xu Y, Chen SY, Ross KN, Balk SP, (2006) Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 66: 7783-7792.
8. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR, (2007) Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem.
9. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW, (2003) Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9: 2416-2425.
10. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE, (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251-258.
11. Kasper S, (2005) Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 94: 279-297.
12. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, et al. (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 102: 1151-1156.
13. Hess-Wilson JK, Daly HK, Zagorski WA, Montville CP, Knudsen KE, (2006) Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res 66: 11998-12008.
14. Wang X, Deng H, Basu I, Zhu L, (2004) Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein. Cancer Res 64: 1377-1385.
15. Verras M, Lee J, Xue H, Li TH, Wang Y, et al. (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67: 967-975.
16. Li J, Wang E, Rinaldo F, Datta K, (2005) Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 24: 5510-5520.
17. Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, et al. (2007) Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 121: 999-1008.
18. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, et al. (2006) PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66: 1329-1338.
19. Rambeaud JJ, (1999) Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol 35 (Suppl 1): 32-36.
20. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P, (1998) Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1: 289-296.
21. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, et al. (2006) Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8: 1291-1297.
22. Campisi J, d'Adda di Fagagna F, (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
23. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, et al. (2008) Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology 54: 92-99.
24. Prieur A, Peeper DS, (2008) Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 20: 150-155.
25. Guo X, Mills AA, (2007) p63, cellular senescence and tumor development. Cell Cycle 6: 305-311.
26. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, et al. (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 19: 1986-1999.
27. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, et al. (2006) Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 66: 8598-8607.
28. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752.
29. Kokontis JM, Hay N, Liao S, (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
30. Isaacs JT, (2008) Prostate stem cells and benign prostatic hyperplasia. Prostate 68: 1025-1034.
31. Halazonetis TD, Gorgoulis VG, Bartek J, (2008) An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355.
32. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS, (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
33. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ, (1999) Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384.
34. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572.
35. Deschenes C, Vezina A, Beaulieu JF, Rivard N, (2001) Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology 120: 423-438.
36. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
37. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, et al. (2008) JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate 68: 924-934.
38. Tokar EJ, Ancrile BB, Cunha GR, Webber MM, (2005) Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 73: 463-473.
39. Keyes WM, Mills AA, (2006) p63: a new link between senescence and aging. Cell Cycle 5: 260-265.
40. Ferbeyre G, (2002) PML a target of translocations in APL is a regulator of cellular senescence. Leukemia 16: 1918-1926.
41. Blagosklonny MV, (2009) Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 8: 1883-1887.
42. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, et al. (2009) Rapamycin decelerates cellular senescence. Cell Cycle 8: 1888-1895.
43. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV, (2010) Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 107: 9660-9664.
44. Demidenko ZN, Blagosklonny MV, (2008) Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 7: 3355-3361.
45. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
46. Dankort D, Filenova E, Collado M, Serrano M, Jones K, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384.
47. Rossi DJ, Jamieson CH, Weissman IL, (2008) Stems cells and the pathways to aging and cancer. Cell 132: 681-696.
48. Stewart JR, O'Brian CA, (2005) Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol Cancer Ther 4: 726-732.
49. Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, et al. (1996) Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma. J Cell Physiol 169: 269-280.
50. Gavrielides MV, Gonzalez-Guerrico AM, Riobo NA, Kazanietz MG, (2006) Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells. Cancer Res 66: 11792-11801.
51. Lee JJ, Lee JH, Ko YG, Hong SI, Lee JS, (2010) Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species. Oncogene 29: 561-575.
52. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, et al. (2002) Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 21: 2180-2188.
53. Burhans WC, Heintz NH, (2009) The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47: 1282-1293.
54. Grisanzio C, Signoretti S, (2008) p63 in prostate biology and pathology. J Cell Biochem 103: 1354-1368.
55. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, et al. (2001) Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61: 8135-8142.
56. Reiner T, de Las Pozas A, Parrondo R, Perez-Stable C, (2007) Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Mol Cancer Res 5: 1171-1179.
57. Signoretti S, Loda M, (2006) Defining cell lineages in the prostate epithelium. Cell Cycle 5: 138-141.
58. Beaudry VG, Attardi LD, (2009) SKP-ing TAp63: stem cell depletion, senescence, and premature aging. Cell Stem Cell 5: 1-2.
59. Calabro V, Mansueto G, Santoro R, Gentilella A, Pollice A, et al. (2004) Inhibition of p63 transcriptional activity by p14ARF: functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol Cell Biol 24: 8529-8540.
60. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, et al. (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A 104: 12679-12684.
61. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, et al. (2001) PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb. J Biol Chem 276: 43491-43494.
62. Leontieva OV, Gudkov AV, Blagosklonny MV, (2010) Weak p53 permits senescence during cell cycle arrest. Cell Cycle 9: 4323-4327.
63. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, et al. (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2: 344-352.
64. O'Mahony OA, Steinkamp MP, Albertelli MA, Brogley M, Rehman H, et al. (2008) Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res 6: 1691-1701.
65. Coppe JP, Desprez PY, Krtolica A, Campisi J, (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
66. Itahana K, Campisi J, Dimri GP, (2007) Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 371: 21-31.